Algo version: 0.98b
DRMAW is listed at the NASDAQ Exchange
DRMAW [DRMAW]
NASDAQ Sector: Healthcare Industry:Biotechnology

Is DRMAW stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Dermata Therapeutics, 10 years ago, but if you had invested on Friday 13th of August 2021 when the price was $1.110, you would have made a loss of $-1.102 per share or -99.24%

No, the average daily trading liquidity for Dermata Therapeutics, is $169 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

Dermata Therapeutics, has no real debt, which is good in periods of high inflation. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for Dermata Therapeutics, to be medium [0.6 out of 1]